health crisis and economic recession. According to data 
from WHO, there have been more than 660 million re -
ported cases and more than 6.7 million deaths, as of 
January 2023. Vaccines have been widely and effectively 
used to reduce disease severity and a number of drugs 
have been approved for clinical use, including the small- 
molecule drugs Paxlovid and Veklury and several 
monoclonal antibodies (mAbs): bebtelovimab, bamlani -
vimab, etesevimab, Xevudy (sotrovimab), REGEN- 
COV (casirivimab and imdevimab), and Evusheld (cil -
gavimab and tixagevimab) [1â€“3] . 
Since the first cases were reported in China, Severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
has mutated rapidly and multiple variants have ap -
peared. From the Wuhan strain to currently dominant 
Omicron strains ( Figure 1 a, phylogenetic tree), the virus 
has gained increased transmissibility and immune es -
cape. Many mAbs, including approved therapeutic ones